CORRELATION OF SERUM VISFATIN WITH ANTHROPOMETRIC AND GLYACEMIC PARAMETERS IN NON-DIABETIC SUBJECTS WITH AND WITHOUT PARENTAL HISTORY OF TYPE II DIABETES MELLITUS

  • Tashfeen Ikram Rashid Latif Medical College, Lahore, Pakistan
  • Muniza Saeed Postgraduate Medical Institute/Ameer-ud-Din Medical College Lahore, Pakistan
  • Sadia Islam Rashid Latif Medical College Lahore, Pakistan
  • Zunairah Hamayun Multan Medical and Dental College, Multan, Pakistan
  • Mariam Pervaiz Postgraduate Medical Institute/Ameer-ud-Din Medical College Lahore, Pakistan
  • Abida Maroof Postgraduate Medical Institute/Ameer-ud-Din Medical College Lahore, Pakistan
Keywords: Visfatin, Offspring, T2DM, Insulin resistance, IR, Beta cell function, Insulin sensitivity, Diabetes mellitus, diabetics, Type II diabetes mellitus

Abstract

Background: Visfatin has insulin like metabolic effects and has a key role in insulin secretion in response to glucose stimulus. This existed link of visfatin with obesity and glucose metabolism is still to be explored and debatable. We aimed to find out the correlation between visfatin and selected anthropometric and biochemical parameters in non-diabetic subjects with type II diabetic parents and with non-diabetic parents. Methods: This cross-sectional analytic study was conducted at the Diabetes Clinic of Lahore General Hospital and Department of Physiology, Postgraduate Medical Institute, Lahore. It comprised of 40 on-diabetic subjects with non-diabetic parents (Group I) aged 30–50 years, and 40 age and sex matched non-diabetic subjects with type II diabetic parents (Group II). Blood pressure, BMI and waist hip ratio, fasting levels of serum visfatin, insulin and glucose were measured and indices of insulin resistance (HOMA-IR), sensitivity (HOMA-%S) and beta cell function (HOMA-%β) were calculated. Results: Serum visfatin did not correlate with any of the anthropometric and glycaemic parameters assessed in group I and II. However, in combined analysis of female non-diabetic subjects, a statistically significant negative correlation between serum visfatin and waist circumference/waist hip ratio, and a positive correlation of serum visfatin with insulin sensitivity index (HOMA-%S) was found. Conclusion: A decline in visfatin production is seen with increasing visceral obesity in non-diabetic female subjects. The fall in visfatin levels seems to play a part in lowering insulin sensitivity in them.

Pak J Physiol 2021;17(2):10–4

References

World Health Organization. Key Facts. Obesity and overweight. Available online: https://www.who.int/news-room/fact-sheets/detail/obesity-and-overweight# [Assessed 31st January 2021].

World Health Organization – Diabetes country profiles, 2016. Geneva, Switzerland: World Health Organization. Geneva, Switzerland: World Health Organization.

Zorena K, Jachimowicz-Duda O, Ślęzak D, Robakowska M, Mrugacz M. Adipokines and Obesity. Potential link to Metabolic disorders and Chronic Complications. Int J Mol Sci. 2020; 21(10): 1-18.

Zhang LQ, Heruth DP, Ye SQ. Nicotinamide phosphoribosyltransferase in human diseases. J Bioanal Biomed. 2011; 7(3): 13-25.

Fukuhara A, Matsuda M, Nishizawa M, Segawa K, Tanaka M, Kishimoto K, Matsuki Y, Murakami M, Ichisaka T, Murakami H, Watanabe E, Takagi T, Akiyoshi M, Ohtsubo T, Kihara S, Yamashita S, Makishima M, Funahashi T, Yamanaka S, Hiramatsu R, Matsuzawa Y, Shimomura I, Visfatin: a protein secreted by visceral fat that mimics the effects of insulin. Science. 2005; 307(5708): 426-430.

Friebe D, Neef M, Kratzsch J, Erbs S, Dittrich K, Garten A, Petzold-Quinque S, Blüher S, Reinehr T, Stumvoll M, Blüher M, Keiss W, Körner A. Leucocytes are a major source of circulating nicotinamide phosphoribosyltransferase (NAMPT)/pre-B cell colony (PBEF)/visfatin linking obesity and inflammation in humans. Diabetologia. 2011; 54(5): 1200-1211.

Skop V, Kontrová K, Zídek V, Pravenec M, Kazdová L, Mikulík K, et al. Autocrine effects of visfatin on hepatocyte sensitivity to insulin action. Physiol Res. 2010; 59(4): 615-618.

Samal B, Sun Y, Stearns G, Xie C, Suggs S, McNiece I. Cloning and characterization of the cDNA encoding a novel human pre-B-cell colony-enhancing factor. Mol Cell Biol. 1994; 14(2): 1431-1437.

Revollo JR, Korner A, Mills KF, Satoh A, Wang T, Garten A et al. Nampt/PBEF/Visfatin regulates insulin secretion in β cells as a systemic NAD biosynthetic enzyme. Cell Metab. 2007; 6(5): 363-375.

Misra A, Srivastava U. Obesity and dyslipidemia in South Asians. Nutrients. 2013; 5(7): 2708–2733.

World Health Organization. WHO STEPS Surviellance Manual: The WHO STEPwise approach to noncommunicable disease risk factor surveillance. 2017. Geneva, Switzerland: World Health Organization.

Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC. Homeostasis model assessment: insulin resistance and β-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia. 1985; 28(7): 412-419.

Wafa AM, Bakr AM, El Aal IA, Nagi AM. Plasma visfatin level in adult Egyptians with android obesity. Egypt J Obes Diabetes Endocrinol, 2017; 3(1):10-14.

Olszanecka-Glinianowicz M, Kocelak P, Nylec M, Chudek J, ZaHorska-Markiewicz B. Circulating visfatin level and visfatin/insulin ratio in obese women with metabolic syndrome. Arch Med Sci. 2012; 8(2): 214-218.

Gouranton E, Romier B, Marcotorchino J, Tourniaire F, Astier J, Peiretti F et al. Visfatin is involved in TNFα-mediated insulin resistance via an NAD+/Sirt1/PTP1B pathway in 3T3-L1 adipocytes. Adipocyte. 2014; 3(3): 180-189.

de Luis DA, Aller R, Gonzalez Sagrado M, Conde R, Izaola O, de la Fuente B. Serum visfatin levels and metabolic syndrome criteria in obese female subjects. Diabetes Metab Res Rev. 2013; 29(7):576‐581.

Kamińska A, Kopczyńska E, Bronisz A, Żmudzińska M, Bieliński M., Borkowska A, et al. An evaluation of visfatin levels in obese subjects. Endokrynol Pol. 2010; 61(2): 169-173.

Agueda M, Lasa A, Simon E, Ares R, Larrarte E, Labayen I. Association of circulating visfatin concentrations after insulin resistance and low-grade inflammation after dietary energy restriction in Spanish obese non-diabetic women: role of body composition changes. Nutr Metab Cardiovasc Dis. 2012; 22(3): 208-214.

Jian WX, Luo TH, Gu YY, Zhang HL, Zheng S, Dai M et al. The visfatin gene is associated with glucose and lipid metabolism in a Chinese population. Diabet Med. 2006; 23(9): 967-973.

Baltaci D, Tuncel MC, Cetinkaya M, Gunduz MT, Ozbey Z, Admis O. Evaluation of Visfatin in Patients with Obesity, Metabolic Syndrome, Insulin resistance and Impaired Glucose Tolerance; Case-Control Study. Acta Med Anatol. 2016; 4(2): 61-67.

Downloads

Download data is not yet available.
Published
2021-06-30
How to Cite
1.
Ikram T, Saeed M, Islam S, Hamayun Z, Pervaiz M, Maroof A. CORRELATION OF SERUM VISFATIN WITH ANTHROPOMETRIC AND GLYACEMIC PARAMETERS IN NON-DIABETIC SUBJECTS WITH AND WITHOUT PARENTAL HISTORY OF TYPE II DIABETES MELLITUS. PJP [Internet]. 30Jun.2021 [cited 27Sep.2021];17(2):10-4. Available from: http://pjp.pps.org.pk/index.php/PJP/article/view/1335